Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:IBRX

ImmunityBio Q1 2026 Earnings Report

ImmunityBio logo
$7.76 -0.62 (-7.40%)
Closing price 04:00 PM Eastern
Extended Trading
$7.60 -0.16 (-2.06%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

ImmunityBio EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.54
One Year Ago EPS
N/A

ImmunityBio Revenue Results

Actual Revenue
$44.21 million
Expected Revenue
$43.07 million
Beat/Miss
Beat by +$1.14 million
YoY Revenue Growth
N/A

ImmunityBio Announcement Details

Quarter
Q1 2026
Date
5/7/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:30AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

ImmunityBio's Q1 2026 Press ReleasePress Release
(8-K)
ImmunityBio's Q1 2026 Quarterly reportQuarterly report
(10-Q)

ImmunityBio Earnings Headlines

Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox
May 7 at 1:48 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IBRX/pressreleases/1774338/deadline-is-may-26-2026-to-lead-in-securities-class-action-against-immunitybio-inc-nasdaq-ibrx-contact-kaplan-fox/
IBRX bulls shrug off earnings loss -- retail traders eye a crucial FDA deadline
May 7 at 1:48 PM  |  msn.comhttps://www.msn.com/en-us/money/general/ibrx-bulls-shrug-off-earnings-loss-retail-traders-eye-a-crucial-fda-deadline/ar-AA22BD6v
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 7 at 1:00 AM  |  American Alternative (Ad)
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
May 7 at 12:15 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290355/673/en/rosen-the-first-filing-firm-encourages-immunitybio-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-first-filed-by-the-firm-ibrx.html
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
May 7 at 12:12 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290354/0/en/immunitybio-inc-ibrx-class-action-lawsuit-seeks-recovery-for-investors-may-26-2026-deadline-contact-kessler-topaz-meltzer-check-llp.html
DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
May 7 at 12:08 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290351/0/en/deadline-alert-for-smci-ibrx-and-pins-the-law-offices-of-frank-r-cruz-reminds-investors-of-class-actions-on-behalf-of-shareholders.html
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. Anktiva is being evaluated in combination with tumor-targeting monoclonal antibodies and immune checkpoint inhibitors for treatment of non–muscle-invasive bladder cancer as well as other solid tumors. In parallel, ImmunityBio is advancing novel T cell receptor (TCR) therapies and off-the-shelf NK cell products aimed at solid and hematologic malignancies.

Beyond oncology, the company has pursued viral-vectored vaccine candidates for infectious diseases, including a Phase 1 program for COVID-19. These efforts leverage a proprietary human adenovirus (hAd5) backbone intended to elicit robust cellular and humoral immune responses. ImmunityBio’s integrated approach combines cell engineering, cytokine biology and vaccine technology to build a diversified pipeline across multiple therapeutic areas.

Founded as NantKwest and rebranded to ImmunityBio in 2020, the company operates under the leadership of CEO Tarek Tantawi and was co-founded by biotech entrepreneur Dr. Patrick Soon-Shiong. Headquartered in Culver City, California, ImmunityBio conducts preclinical research and clinical trials in North America, Europe and Australia. The company maintains collaborations with academic institutions, government agencies and industry partners to accelerate development and regulatory filings for its immunotherapy candidates.

View ImmunityBio Profile
Earnings Tools